Corporate Profile

Corporate Profile

Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. To achieve this mission, Teleflex is committed to the following: investing in technology and developing our pipeline; leveraging and building our core franchises and distribution channels; attracting, developing and retaining talented employees around the world; and continuing to build financial strength by expanding our margins and maintaining strong cash flow all in an effort to successfully grow our reputation as a solid investment and a profitable, strong employer. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We sell our products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors. Our products are used in a wide variety of markets and are not dependent upon any one end-market or procedure.

We are focused on achieving consistent , sustainable and profitable growth by increasing our market share and improving operating efficiencies through:

  • • the development of new products and product line extensions;

  • • the investment in new technologies and broadening their applications;

  • • the expansion of the use of existing products in existing markets, as well as in new geographic markets;

  • • leveraging our direct sales force and distribution network with new products, manufacturing and distribution facility rationalization and achieving economies of scale as we continue to expand; and

  • • the potential broadening of our product portfolio through select acquisitions, licensing arrangements and partnerships that enhance, extend or expedite our development initiatives or our ability to increase our market share.
Recent NewsMore »
The Difficult Airway Society (DAS) Launches Inaugural Project Grant to Support Formal Evaluation of Second-Generation Supraglottic Airway Devices (SADs) in Accordance with ADEPT (Airway Device Evaluation Project Team) Guidance
WAYNE, Pa.--(BUSINESS WIRE)--Aug. 18, 2016-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has today announced its support of the Difficult Airway Society with the launch of the first research grant directed to ADEPT Guidance. The research grant, which will be funded by Teleflex and administered by the Difficult Airway Society, will support the evaluation of second-generation SADs. ... 
Teleflex Launches New Second-Generation 2.9 mm Percuvance® System – A Breakthrough Advance that Makes Percutaneous Approach to Laparoscopic Procedures Even Less Invasive
First U.S. Clinical Laparoscopic Procedure with New Percuvance® System Performed at the Duke Center for Metabolic and Weight Loss Surgery Teleflex Launches Ambitious Efforts to Accelerate Growing Acceptance Worldwide of Percutaneous Laparoscopy Now Performed in 14 Countries WAYNE, Pa.--(BUSINESS WIRE)--Aug. 15, 2016-- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, ha... 
Teleflex Announces Quarterly Dividend
WAYNE, Pa.--(BUSINESS WIRE)--Jul. 28, 2016-- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2016 to shareholders of record at the close of business on August 15, 2016. The company offers a Dividend Reinvestment & Direct Stock Purchase and Sale Plan. For information about the Pla... 
Teleflex Reports Second Quarter 2016 Results
Second Quarter Revenues of $473.6 million, Up 4.8% Versus Prior Year Period; Up 5.0% on Constant Currency Basis Second Quarter GAAP Diluted EPS of $1.25, Up 34.4% Over the Prior Year Period Second Quarter Adjusted Diluted EPS of $1.89, up 33.1% Reaffirmed 2016 Guidance Ranges for As-Reported Revenue Growth of 3.0% to 4.0% and Constant Currency Revenue Growth of 5.0% to 6.0% Raised 2016 Guidance Range for GAAP Dilute... 
Upcoming EventsMore »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Print Page Print Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet